Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Pathol ; 159(5): 1957-69, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11696457

ABSTRACT

Bovine thrombin is used as an aid to hemostasis in medical and surgical procedures. At least 500,000 Americans are exposed to this therapeutic annually and reports suggest that exposure is associated with the development of autoreactive antibodies. To determine whether bovine thrombin can induce pathological autoimmunity we exposed nonautoimmune-prone galactose-alpha1-3-galactose-deficient mice to the two bovine thrombin preparations currently approved for use in the United States. We found that, like humans exposed to bovine thrombin, mice developed an immune response against the therapeutic and the xenogeneic carbohydrate galactose-alpha1-3-galactose, and some mice developed autoantibodies against clotting factors. Further, unexpectedly, a single exposure to this therapeutic also induced autoimmunity with features characteristic of systemic lupus erythematosus including antibodies against nuclear antigens, native DNA, double-stranded DNA, and cardiolipin. High levels of these autoantibodies correlated with glomerulonephritis in all mice evaluated. This autoimmune syndrome was detected in mice 15 weeks after a secondary exposure to bovine thrombin and female mice were found to develop the syndrome at a significantly greater frequency than males. Thus, these studies indicate that exposure to bovine thrombin preparations can induce a pathological systemic autoimmune syndrome with lupus-like serology.


Subject(s)
Autoimmunity/immunology , Thrombin/administration & dosage , Thrombin/immunology , Administration, Topical , Animals , Antibodies/immunology , Antibodies, Anticardiolipin/biosynthesis , Antibodies, Antinuclear/analysis , Autoantibodies/immunology , Autoimmune Diseases/immunology , Autoimmune Diseases/pathology , Autoimmune Diseases/psychology , Behavior, Animal , Cattle , DNA/immunology , DNA, Single-Stranded/immunology , Female , Galactosyltransferases/genetics , Galactosyltransferases/immunology , Male , Mice , Mice, Knockout/genetics , Microscopy, Electron , Time Factors
2.
Immunobiology ; 203(4): 650-8, 2001 May.
Article in English | MEDLINE | ID: mdl-11402499

ABSTRACT

Mice lacking the alpha-galactosyl transferase gene (GalT(-/-) mice) have been used extensively as a model for xenotransplantation. Unlike wild type (WT) mice, GalT(-/-) mice do not produce Gal alpha 1-3Gal and are known to produce natural IgM specific for Gal alpha 1-3Gal, as do humans and higher primates. In addition to natural anti-Gal alpha 1-3Gal IgM in GalT(-/-) mice, we identified natural IgM which bound alpha-N-acetylgalactosamine (alpha GalNAc) but not Gal alpha 1-3Gal or blood group A. Although unexpected, these antibodies were expressed at 10-fold greater concentrations in GalT(-/-) mice than in WT mice. One explanation for this unexpected observation is that the production of natural antibodies is affected by self-antigen(s) that are similar but not identical to targets recognized by the natural antibody. Thus, the natural humoral immune system may be unresponsive to "near-self" antigens even though the individual is not tolerant to those antigens. Another explanation for the unexpected results is that there may be unanticipated and uncharacterized differences between GalT(-/-) mice and WT mice. These studies underscore the need to extensively characterize phenotypes in KO mice and indicate that the relationship between genotype and the natural immune repertoire can be complex.


Subject(s)
Acetylgalactosamine/immunology , Antibody Formation , Galactosyltransferases/deficiency , Animals , Galactosyltransferases/genetics , Genotype , Humans , Immunity, Innate , Immunoglobulin Isotypes/biosynthesis , Mice , Mice, Inbred DBA , Mice, Knockout , Self Tolerance
3.
Clin Immunol ; 98(2): 175-9, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11161973

ABSTRACT

Blocking the elicited humoral immune response has proven useful in treating individuals with autoimmune disorders or those who are at risk of developing antibodies which might be pathologic, e.g., transplant patients. Unfortunately, humoral immunity has evaded efforts at ablation and those therapies aimed at ameliorating it have resulted in only partial success. In addition, some of the current anti-humoral therapies not only target B-cells but also cross-react with other elements of immune response, making these therapies nonspecific. Thus there is a need in the clinical arena for specific anti-humoral therapies. Here we report the impact of infusion of a chimeric monoclonal, an anti-CD20 IgG, on the primary humoral and memory response against a simple hapten (DNP) in a nonhuman primate model. Anti-CD20 IgG interfered with the elicited humoral response and with the memory response when administered prior to antigen exposure. Furthermore, we provide evidence that anti-CD20 blocks the humoral response by eliminating those B-cells capable of responding to the hapten.


Subject(s)
Antibodies, Monoclonal/pharmacology , Antibody Formation/drug effects , Antigens, CD20/immunology , B-Lymphocyte Subsets/drug effects , Dinitrobenzenes/immunology , Haptens/immunology , Immunoglobulin G/pharmacology , Immunologic Memory/drug effects , Immunosuppressive Agents/pharmacology , Animals , Antibodies, Monoclonal, Murine-Derived , Antigens, CD19/analysis , B-Lymphocyte Subsets/immunology , Flow Cytometry , Hemocyanins/immunology , Humans , Immunization , Immunization Schedule , Immunoglobulin Class Switching/drug effects , Immunosuppressive Agents/immunology , Papio , Rituximab
4.
J Immunol Methods ; 246(1-2): 61-8, 2000 Dec 01.
Article in English | MEDLINE | ID: mdl-11121547

ABSTRACT

Natural anti-carbohydrate antibodies in humans play a key role in natural immunity and in recognition of allogeneic and xenogeneic antigens. Presumably, natural anti-carbohydrate antibodies in mice have similar functions; but these antibodies have not been extensively characterized. An assay was developed and used to screen for anti-carbohydrate IgM in the serum of BDF-1 mice. Among the natural anti-carbohydrate IgM identified, anti-betaGlcNAc IgM were the most abundant. Anti-betaGlcNAc IgG was not detected. Levels of anti-betaGlcNAc IgM were very low in 3-week-old BDF-1 mice and increased until 5 to 7 months of age. Levels of serum anti-betaGlcNAc IgM similar to those in BDF-1 mice were found in the serum of some strains related to the BDF-1 strain (DBA and C57BL/6) and in BDF mice lacking the galactosyl transferase gene. However, in two strains unrelated to the BDF-1 strain (FVB and SJL), levels of anti-betaGlcNAc IgM were less than one-tenth of those found in BDF-1 mice. These results provide considerable insight into the effect of age on the production of natural anti-carbohydrate antibodies in mice and indicate that production of those antibodies is strongly dependent on the strain of mouse. These studies will help in future development of murine models for studying the biological and medical roles of natural anti-carbohydrate antibodies.


Subject(s)
Acetylglucosamine/immunology , Aging/immunology , Immunoglobulin M/immunology , Animals , Enzyme-Linked Immunosorbent Assay , Immunoglobulin M/blood , Mice , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Inbred DBA , Species Specificity
5.
Br J Cancer ; 83(2): 219-24, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10901374

ABSTRACT

Thymidine phosphorylase (TP) is an essential enzyme for the biochemical activation of 5-fluorouracil (5-FU). Interferon upregulates TP in vivo, although the dose and schedule of interferon for optimal biomodulation of 5-FU is not known. In this study, TP activity was measured in peripheral blood lymphocytes (PBLs) from patients with advanced carcinoma receiving treatment with 5-FU and folinic acid. Cohorts of patients were treated with interferon alpha (IFNalpha), immediately prior to 5-FU/folinic acid, at doses of 3 MIU m(-2), 9 MIU m(-2) and 18 MIUm(-2). IFNalpha was administered on day 0 cycle two, day-1 and day 0 cycle three and day-2, day-1 and day 0 cycle four. A fourth cohort was treated with IFNalpha 9 MIU m(-2) three times per week from cycle 2 onwards. Twenty-one patients were entered into the study with 19 evaluable for response. Six patients (32%) had stable disease and 13 (68%) progressive disease. There were no grade-IV toxicities. TP activity was detected in PBLs from all patients with wide interpatient variability in constitutive TP activity prior to chemotherapy, and in response to IFNalpha. 5-FU/folinic acid alone did not induce TP activity but a single dose of IFNalpha led to upregulation of TP within 2 h of administration with a further increase by 24 h (signed rank test, P = 0.006). TP activity remained elevated for at least 13 days (signed rank test, P= 0.02). There were no significant differences in TP activity between schedules or with additional doses of IFNalpha. A single dose of IFNalpha as low as 3 MIU m(-2) can cause sustained elevation of PBL TP activity in vivo indicating that biochemical markers are important pharmacodynamic endpoints for developing optimal schedules of IFNalpha for biomodulation of 5-FU.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma/enzymology , Thymidine Phosphorylase/biosynthesis , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Carcinoma/drug therapy , Dose-Response Relationship, Drug , Enzyme Induction/drug effects , Fluorouracil/administration & dosage , Fluorouracil/adverse effects , Humans , Interferon-alpha/administration & dosage , Interferon-alpha/adverse effects , Leucovorin/administration & dosage , Leucovorin/adverse effects , Middle Aged
6.
J Cardiovasc Pharmacol ; 20(4): 678-82, 1992 Oct.
Article in English | MEDLINE | ID: mdl-1280727

ABSTRACT

Clentiazem is an 8-chloro-substituted derivative of diltiazem. We compared the relative potency of clentiazem with that of diltiazem, verapamil, nifedipine, and nimodipine in isolated rabbit right atria and vascular smooth muscle removed from various arterial beds. In experiments with isolated right atria, calcium channel blockers were added cumulatively to study relative cardiodepressive potencies (as compared with vascular effects) with the following results: verapamil greater than or equal to diltiazem greater than clentiazem greater than or equal to nimodipine much greater than nifedipine. The aorta, pulmonary, renal, mesenteric, coronary, and basilar arteries were removed, cut helically in strips, and mounted in isolated tissue baths to measure isometric force. Vessels were contracted with either 40 mM KCl (opening voltage-operated calcium channels) or 1 x 10(-5) M norepinephrine (NE, opening receptor-operated calcium channels). Cumulative dose-response curves were generated for relaxation with each calcium channel blocker. All compounds were more potent at relaxing potassium-induced contractions than NE-induced contractions. In vessels precontracted with KCl, neither diltiazem, verapamil, or nifedipine showed selectivity for basilar artery as compared with the mesenteric artery. Both clentiazem and nimodipine were selective (6- and 30-fold, respectively) for basilar artery in blocking potassium-induced contractions. When NE was used to contract the arteries, clentiazem (12-fold), diltiazem (8-fold), verapamil (8-fold), and nifedipine (153-fold) were all more potent in relaxing the contraction in basilar artery than in mesenteric artery. Nimodipine failed to demonstrate selectivity for basilar artery as compared with mesenteric artery contracted with NE.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Calcium Channel Blockers/pharmacology , Hemodynamics/drug effects , Animals , Calcium/metabolism , Calcium Channels/metabolism , In Vitro Techniques , Isometric Contraction/drug effects , Membrane Potentials , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/metabolism , Rabbits , Vasoconstriction/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...